Enforcement Trends: OIG Calls Out CMS for Not Preventing Medicare Genetic Testing Overpayments
Inadequate CMS oversight resulted in $888.2 million in improper payments for the highest reimbursing molecular pathology genetic tests, report says.
Enforcement-nir
Subscribe today for access to
Articles and Reports
Enforcement Trends: The Urine Drug Testing Crackdown and Three Ways to Avoid It
False billing of urine drug tests (UDTs) continues to be a focus for enforcement agencies in 2023, here’s how to avoid compliance issues.
OIG Semi-Annual Report Calls Out Drug, Genetic, and COVID-19 Testing Fraud
These three lab testing areas were the main sources of fraud and abuse revealed in the OIG’s latest Semi-Annual Report to Congress.
Enforcement Trends: Investment Return on Fraud Fighting Continues to Decline
From - National Intelligence Report
Although it's still a profitable endeavor, enforcing federal health care fraud laws isn't providing the investment returns of yesteryears…
DOJ Explains What It Wants from a Compliance Program
...
Already a member? Log in here
New OIG Report Confirms that Labs Are Still on the Enforcement Radar
...
Already a member? Log in here
Case of the Month: FDA Issues Warning Letter for Unapproved Changes to Approved Assay
From - National Intelligence Report
As a rule of thumb, FDA approvals are a snapshot applicable only to the product as it exists at the time of review and approval…
Enforcement Trends: Feds Targeting Commercial & Private-Pay, Not Just Medicare Fraud
From - National Intelligence Report
Risk of federal prosecution for health fraud and abuse applies only when you deal with Medicare, TRICARE or other federal health programs…
Case of the Month: Milwaukee Clinic the Latest MD-Owned Lab Busted for Urine Drug Test Abuses
From - National Intelligence Report
Fraudulent utilization and billing of urine drug screening first became a priority for federal enforcers since the…
Medicaid Fraud Enforcement Trends By the Numbers
From - National Intelligence Report
A new report from OIG details Medicare Fraud Control Unit (MCFU) enforcement activity in fiscal year…
From Blood Screen to Silver Screen: The Theranos Story Goes Hollywood
...
Already a member? Log in here
Compliance Alert: FDA Warning Letter to Inova Genomics Laboratory
Enforcement Trends: CMS Looks to Recover $66.3 Million in Improper Specimen Validity Test Payments
From - National Intelligence Report
The opioid crackdown has made urine drug testing an even greater priority for federal health fraud enforcers. One principle target is specimen validity testing…
